HealthpointCapital is a values-driven, research-based private equity firm exclusively focused on the musculoskeletal sector — specifically orthopedics and dental.

HealthpointCapital manages in excess of $800 million of institutional capital.
Values

There are core values on which we as a firm pride ourselves. These values are the driving forces of our business. We live up to these standards in all facets of our culture.

Within the Firm, we hold respect for the individual as a cornerstone of our culture. We are committed to treating each employee with dignity, and we value each opinion. This makes communication within the organization a two-way street and ensures that we attract a special kind of person who is willing to grow, contribute and live the Firm's values. In addition, we support our employees by setting clear performance objectives that align each person to the goals of the Firm. We continually strive to develop our employees to their maximum potential and support them in attaining their goals so they can be uniquely productive on behalf of the Firm.

Customer service is primary, whether to our financial partners, operating management teams, clinical community, advisors or board members. We aim to change and respond to the expectations of all of our constituents by aligning our business appropriately and fairly. The goal is to exceed those expectations by upholding strong personal relationships, supporting our management teams on-site and using our independent professional judgment to advance the objectives of our constituents consistent with the highest standards.

Efficiency and profitability are other driving factors for our Firm. Responsibility to our investors to spend our resources wisely is critical to our business. These resources are not limited to money, but also include time, skills and knowledge of our staff.

The pursuit of excellence is both an internal and external value motivating our Firm. We strive for the highest standards in order to achieve exceptional results. For our team, goals are set, measured and rewarded on an ongoing basis. Most importantly, superior results are expected for our investors, to whom we are committed to achieving attractive returns on a consistent basis.

The integrity of a private equity firm is only as strong as the integrity of its individuals. Embracing sound moral principles, uprightness and honesty, we not only ensure strict compliance with policies, laws and regulations, but we commit to always “do the right thing.” It is our goal to maintain and enhance our reputation as well as the respect we earn by acting ethically at all times.
About Us

HEALTHPOINT CAPITAL is a New York-based private equity firm with excess of $800 million of institutional capital under management. The Firm differentiates from its peers due to its exclusive focus on the orthopedic and dental (musculoskeletal) marketplaces.

Market Opportunity

The musculoskeletal market is the largest sector within the medical device industry with an approximate market capitalization of $115 billion, and worldwide revenues of $44 billion. The sector exhibits a vastly remunerative and compelling area for investment in the global healthcare industry as it is founded on the convergence of an aging population and a high-level of innovation. HEALTHPOINT CAPITAL is uniquely positioned to capitalize on such an opportunity.

The acquisition landscape is also favorable. There are three times as many companies in the orthopedic sector as in the cardiovascular sector, which is rewarding to an investment firm with a single-industry focus. The healthy rate of company formation continually creates new investment opportunities for the Firm. Valuations of target companies are attractive and the worldwide market is in the intermediate phase of consolidation. These dynamics play to HEALTHPOINT CAPITAL’s proven ability to add substantial value during the investment process.

Adding Value

We offer more than capital to our acquisitions. HEALTHPOINT CAPITAL’s firsthand experience in the industry guides strategy and organization development at our portfolio companies. Our global network of industry relationships – surgeons, distributors, management teams and the clinical community – provides proprietary access and allows us to zero in on the most attractive acquisitions in partnership with management.

Differentiated by Research

Our stature in the industry is grounded in a thorough knowledge of the business. HEALTHPOINT CAPITAL has a dedicated research department that underpins our reputation as industry experts. Our research-driven approach, together with a worldwide relationship network, leads directly to unique insight, substantial deal flow and a track record of investment success.
Investments with Impact

Newly-developed orthopedic and dental devices make a measurable, positive difference in patients’ lives. For instance, products from Alphatec help reduce pain for people with spinal problems and focuses on the elderly spine patient. BioHorizons’ dental implants provide patients with a stronger, permanent and more attractive alternative to tooth restoration. Blue Belt Technology provides a revolutionary next generation surgical robotic technology allowing surgeons to more accurately perform complicated surgical procedures ensuring superior patient outcomes. MicroDental laboratories restore dental function and health, improving patient confidence and aesthetics. OrthoAccel sells a removable orthodontic appliance that significantly reduces treatment duration for patients with braces. Finally, China Rehab will provide patients with postoperative, outpatient orthopedic rehabilitation services, a practice relatively absent from the current continuum of care in China. Healthpoint Capital’s investments and corporate development initiatives have brought numerous products to market sooner than they would otherwise have been developed, and have improved clinical outcomes.

We take pride that Healthpoint Capital buyouts are accompanied by a commitment to accelerate growth. We broaden access to our products, create jobs, invest in world-class systems and seek to build and strengthen the overall musculoskeletal industry.

Global Reach

Healthpoint Capital companies serve patients globally, with a distribution presence in North America, Europe, Asia, South America, the Middle East and Africa. In addition, China Rehab is building an outpatient rehabilitation business in China. It is an opportunity to participate in an important high-growth, emerging market and leverage our expertise. This investment has been developed through the Firm’s longstanding partnerships with leading Chinese orthopedic surgeons. Our international investor base, representing foundations, endowments, financial institutions and private investors, is committed to the industry’s growth and innovation.

Clinical Concentration

In a marketplace where innovation is paramount, knowing the product and procedure experts gives us insight into new business opportunities. This is why we cultivate and leverage relationships with leading orthopedic and dental professionals. We hold quarterly meetings with our Scientific Advisory Board, meet surgeons at clinical conferences and foster ad-hoc relationships.

These collaborations direct Healthpoint Capital’s research activity and play a critical role in the investment process by keeping us up to date on the most promising sectors and companies. After an investment, we ensure specialized clinical knowledge informs strategy at portfolio companies through individual Scientific Advisory Boards. This focus contributes to improved patient outcomes – which lead to long-term value creation.
The Firm focuses exclusively on private equity investments in musculoskeletal devices in order to:

- Capitalize on industry growth, which is driven by demographics and innovation.

- Utilize our industry expertise and dedicated research team to create proprietary deal flow in an industry with over 1,600 companies.

- Draw on our successful experience as long-standing healthcare private equity investors to grow the portfolio companies we invest in or acquire.

- Leverage our global reach and experience to invest in foreign companies that can be successfully expanded in the United States through our surgeon and distributor relationships as well as our unique strategic position.

The Firm invests in only the most exceptional companies in the musculoskeletal industry with proven technologies, outstanding management teams and strong growth potential.

**Healthpoint Capital** is the first stop for orthopedic and dental companies that require growth capital.
Musculoskeletal Industry - Strong Growth Drivers

Aging of the Population
Growth and aging of the worldwide population will be a principal driver of unit growth in orthopedic incidents, treatments and ultimately device sales. “Baby boomers”, or the 45-and-over portion of the US population, have a higher expectation of an active lifestyle, and the rapidly growing portion of the population represents a demographic “sweet spot” in the demand for orthopedic devices.

Obesity
Obesity is on the rise. Two-thirds of men and women 20 years and older are overweight, and almost one-third are obese. Obesity increases the risk of orthopedic-related conditions such as osteoarthritis and degenerative disc disease - two conditions that often require surgical intervention.

Market Performance
Over the recent decade, the industry has grown from just over $10 billion in revenues to a mature global market with an estimated $44 billion in revenues and $115 billion in market capitalization in 2013.
Musculoskeletal Industry

New Technologies
Orthopedic technologies today are, in many respects, underdeveloped. Many surgical implants retain simple mechanical and material characteristics. New orthopedic procedures and technologies are coming online, however, and innovation is expected to continue.

- Minimally invasive surgery techniques in spine, hip, knee and shoulder
- Outpatient hip and knee procedures (including full and partial replacement)
- Disruptive digital business model in restorative dentistry
- Resorbable implants that are replacing conventional metal implants
- Game-changing cartilage repair technologies and implants
- Osteoporotic fracture management
- CAD/CAM dental prosthesis
- Novel surface treatments, which provide greater implant fixation and aesthetics
- Orthobiologics, such as bone morphogenic proteins, growth factors, peptides, anti-adhesives and stem cell therapies
- Early intervention spinal disc repair and emerging spinal soft tissue technologies
- Diagnostic and non-surgical pain management devices
- Surgical Robotics

Blue Belt Navio PFS Hand Piece
Musculoskeletal Industry

Focusing on Innovative and High Growth Segments

Dental Implants
- $4 billion global market
- Highly underpenetrated market
- Superior outcomes compared to traditional treatments
- Shift towards improved aesthetics
- Increasing clinician and professional awareness

Spine
- Emerging, fragmented industry
- Prevalent use of biologic devices
- Active M&A, private placements and IPOs
- Differentiation creates substantial value
- $9 billion worldwide revenues including biologics

Orthodontics
- $2 billion global market
- Game changing innovations rare and therefore valuable
- Strategic acquirers are cash rich
- Underpenetrated non-U.S. markets
- Uptake of orthodontics by general practitioners a growth driver

Robotics
- Robotics and smart instruments are the future of surgery
- Fastest growing segment of medical technology
- Allow for greater precision and accuracy
- Provides ability for more complex procedures
- Next generation is smaller and less expensive
Portofolio Companies

HealthpointCapital portfolio companies represent outstanding platforms in four important segments of the musculoskeletal industry: spine, dental, robotics and extremities.

BioHorizons, Inc. is a medical technology company focused on developing, manufacturing and marketing a broad line of innovative, proprietary and evidence-based dental implants, as well as hard and soft tissue regeneration products, for the replacement of missing teeth. The company has designed its dental implant product portfolio to address the clinical requirements in implant dentistry. Its implant products feature their proprietary Laser-Lok® platform technology as well as its enhanced biomechanically-engineered threads. Henry Schein Inc., the largest dental distributor in the world, purchased 60% of BioHorizons in December, 2013. The combination provides BioHorizons with a significantly larger global distribution network in which to leverage. BioHorizons is headquartered in Birmingham, Alabama and has 321 employees worldwide.

www.biohorizons.com

Dental Implants

“Innovative BioHorizons’ implants deliver the best patient outcomes of any implant I have used. My success rate with BioHorizons exceeds 99% with excellent bone retention and superior esthetic results.”

Carl E. Misch, DDS, MDS

BioHorizons, Inc. is a medical technology company focused on developing, manufacturing and marketing a broad line of innovative, proprietary and evidence-based dental implants, as well as hard and soft tissue regeneration products, for the replacement of missing teeth. The company has designed its dental implant product portfolio to address the clinical requirements in implant dentistry. Its implant products feature their proprietary Laser-Lok® platform technology as well as its enhanced biomechanically-engineered threads. Henry Schein Inc., the largest dental distributor in the world, purchased 60% of BioHorizons in December, 2013. The combination provides BioHorizons with a significantly larger global distribution network in which to leverage. BioHorizons is headquartered in Birmingham, Alabama and has 321 employees worldwide.

www.biohorizons.com

Alphatec Spine

Alphatec Spine, Inc. is one of the largest global independent developers and manufacturers of implants for the surgical treatment of spine disorders. The company is primarily focused on the aging spine which allows it to use its broad product portfolio and pipeline to address one of the largest sectors in the orthopedics industry. Since the Firm’s March 2005 acquisition, Alphatec has attracted world class management talent, expanded its infrastructure and manufacturing capabilities and grown revenues organically by a factor of twelve from $17 million to $200 million. In June 2006, Alphatec completed an $84 million initial public offering, and the Company has raised an additional $163 million through subsequent public offerings. In March 2010, Alphatec acquired Scient’x Groupe, SAS, greatly expanding Alphatec’s global reach and adding the Scient’x technologies to Alphatec’s U.S. distribution. Subsequent to the merger, Alphatec raised $80 million in a public equity offering. Alphatec is now the seventh-largest spine company in the world. Headquatered in Carlsbad, California, Alphatec has over 490 employees worldwide.

www.alphatecspine.com

GLIF

“Systems that allow maximum versatility, efficiency and effectiveness for the surgeon will drive the future of spinal surgery. GLIF, which creates anterior access to the lumbar spine while the patient is prone, will lead that movement.”

Javier Garcia-Bengochea, MD

www.alphatecspine.com

NASDAQ: ATEC
Blue Belt was founded in 2003 and is based in Pittsburgh, Pennsylvania. Its flagship product, the Navio Precision Freehand Sculptor, is a compact, handheld, intelligent tool used to assist the surgeon in accurate bone cutting. The technology uses robotics and navigation software and eliminates the need for the jigs and guides currently used in bone cutting and shaping procedures. It provides the opportunity for surgeons and hospitals to acquire comprehensive surgical robotics capabilities for a fraction of the cost of existing systems and solutions. The Navio PFS enables surgeons to perform operations through smaller incisions with increased visualization, making the procedures less invasive and creates opportunities for new procedures and approaches in the future. Initially focused on the unicompartmental knee market, this technology also has applications in the hip, extremities, neuro and dental markets.

MicroDental is the fourth largest dental laboratory network in the world, producing thousands of individualized dental restorations every day. The company is a pioneer in digital dentistry, utilizing mass customization and scalable automation technologies to provide dentists with a differentiated service experience. MicroDental’s 19 full-service locations are customer oriented, with dedicated teams of highly trained technicians providing case support, product selection and other technical services. Headquartered in Dublin, California, MicroDental has 650 employees throughout North America and services 8,100 dentists in 50 states and six countries.

www.microdental.com
OrthoAccel has commercialized an orthodontic device called AcceleDent™ that significantly reduces the treatment time of any type of orthodontic bracing or aligning process. The treatment time reduction is between 30% and 50%. OrthoAccel is the true First Mover in its field having conducted a successful prospective randomized FDA clinical trial with AcceleDent™ and achieving subsequent FDA approval. The Company has no direct competition and is selling AcceleDent™ both in the USA and in a dozen countries globally. OrthoAccel is based in Houston, Texas.

“OrthoAccel’s technology has the potential to accelerate orthodontic tooth movement by smart, automated devices. Treatment with braces becomes a seasonal episode instead of a multi-year event.”
Dr. Jeremy Mao, DDS, PhD

CHINA REHABILITATION, LTD.

China Rehabilitation, Ltd. (“China Rehab”) is a company formed in Beijing, China that will provide postoperative, outpatient orthopedic rehabilitation services to private pay patients having recently undergone multiple forms of orthopedic surgical interventions. The pilot rehabilitation facility will be located adjacent to Beijing’s leading orthopedic hospital, Ji Shui Tan (JST). The business plan is to roll out a chain of branded for-profit outpatient facilities starting in Beijing and expanding to other major cities such as Shanghai, Guangzhou and Chengdu.

“China Rehabilitation addresses one of the largest unmet needs in China’s healthcare system today.”
Professor Changlong Yu
Nexa Orthopedics, Inc. was founded in 2004 by HealthpointCapital to create the pre-eminent company in extremities surgery through a program of business investments, technology in-licensing, internal development and acquisition. The investment opportunity in the highly fragmented market was based on consolidation and scale, and driven by differentiated technology.

In February 2005, Nexa acquired Futura Biomedical, LLC. Futura manufactured and distributed the only complete line of forefoot arthroplasty products and was a leading innovator of implants for the correction of flexible flatfoot deformities. In the summer of 2005, Nexa acquired the StayFuse™ product line from Pioneer Surgical. Nexa also partnered with OsteoBiologics, Inc. for U.S. distribution of OBI products in hand, foot and ankle surgery. In November 2005, Nexa acquired BioProfile S.A., a French manufacturer of orthopedic extremity products utilizing its novel pyrocarbon. In September 2006, Nexa acquired Axiom Orthopaedics, Inc., a leading innovator in the shoulder arthroplasty market.

HealthpointCapital sold Nexa Orthopedics, Inc. to Tornier in February 2007. The sale of Nexa provided HealthpointCapital Partners, L.P. a 75% internal rate of return on its investment.

www.nexaortho.com
Research

HealthpointCapital has a dedicated Research team on whose insight into markets, technologies and trends industry professionals have come to rely.

Through conference attendance, Scientific Advisory Board interaction, trade group membership, news coverage and blog publication, the Research team has established itself as both a leading resource and an active participant in the industry. They also maintain a proprietary database of more than 1,600 companies. The Research team’s unique role and knowledge base inform and strengthen the Firm’s industry relationships.

Sponsorship

HealthpointCapital is also a member of the Medical Device Manufacturers Association (MDMA), an organization that champions favorable regulatory and market conditions for medical device innovators.

www.medicaldevices.org
HealthpointCapital Completed Transactions

HealthpointCapital

Invests $32 million in

Scient'x S.A.

Scient'x S.A. is a leader in dynamic stabilization and motion preservation spinal implants.

June 28, 2004 New York

A HealthpointCapital company

Has acquired for $4.5 million

Futura Biomedical

Nexa Orthopedics is an emerging leader in extremities orthopedics.

February 23, 2005 New York

HealthpointCapital

Invests $85 million in

Alphatec

Alphatec is one of the largest private providers of spinal implants in the United States and Japan.

March 18, 2005 New York

A HealthpointCapital company

Has acquired 73% of

Surgview

Scient'x S.A. is a leader in dynamic stabilization and motion preservation spinal implants. Based in France, this profitable spinal implant manufacturer possesses a range of fusion and non-fusion products, with a strong market penetration in Western Europe, Asia and, increasingly, the United States, the Company's fastest growing market.

July 4, 2005 Guyancourt, France

Nexa Orthopedics

A HealthpointCapital company

Has acquired substantially all the assets related to

StayFuse™

Nexa Orthopedics is an emerging leader in extremities orthopedics.

July 12, 2005 New York

A HealthpointCapital company

Has acquired for $8 million

Cortek, Inc.

Based in Carlsbad, California, Alphatec is one of the largest privately-held manufacturers of spine surgery implants in the United States and Japan. Alphatec’s core strength is its rapidly growing line of traditional spinal fusion products which is co-developed with prominent orthopedic surgeons.

September 13, 2005 Carlsbad, CA
Based in Deerfield Beach, Florida, BioLok International Inc. is merging cell biology and implant technology to develop and market products for the dental industry.

October 25, 2006                      New York

Nexa Orthopedics is an emerging leader in extremities orthopedics.

November 28, 2005                      New York

A HEALTHPOINT CAPITAL company has acquired for $35 million

ALPHATEC SPINE INC.

Initial Public Offering: 9,300,000 shares $83.7 million

Joint Book-Running Managers:

FIRST ALBANY CAPITAL Deutsche Bank RBC

June 2, 2006

Nexa Orthopedics is an emerging leader in extremities orthopedics.

October 25, 2006                      New York

A HEALTHPOINT CAPITAL company has acquired for $5.5 million

A company has acquired for $97 million

Based in Birmingham, Alabama, BioHorizons is one of the largest privately-owned dental implant companies in the world.

August 21, 2006                      New York

A HEALTHPOINT CAPITAL company has acquired for $25 million

DTI Dental Technologies Inc.

DTI Dental Technologies Inc. is one of the world's largest dental laboratory companies.

August 24, 2006                      New York

A HEALTHPOINT CAPITAL company has acquired for $35 million

-equipped-threads

Based in Deerfield Beach, Florida, BioLok International Inc. is merging cell biology and implant technology to develop and market products for the dental industry.

October 25, 2006                      New York

Nexa Orthopedics is an emerging leader in extremities orthopedics.

September 27, 2006                      New York

Nexa Orthopedics is an emerging leader in extremities orthopedics.

November 28, 2005                      New York
Nexa Orthopedics
A HealthpointCapital company has been acquired for $72.5 million by
Tornier
February 28, 2007 New York

Dental Technologies Inc
A HealthpointCapital company has acquired for $80 million
March 12, 2007 New York

HealthpointCapital has acquired for $111 million
Scient’x
Scient’x S.A. is a leader in dynamic stabilization and motion preservation spinal implants.
November 21, 2007 New York

BIOHorizons
A HealthpointCapital company has acquired for $5.5 million
Based in Cedarhurst, NY, ILS is a leading innovator and provider of technology solutions for the implant dentistry market.
April 15, 2008 New York

HealthpointCapital
invests $10 million in
Alphatec Spine
Thomas Weisel Partners acted as financial advisor
June 4, 2009 New York

Alphatec Spine
A HealthpointCapital company has acquired for $152.2 million
March 29, 2010 New York
Alphatec Holdings Inc.

16,000,000 Shares Common Stock
$80 million

Joint Book-Running Managers:

Jefferies  CANACCORD Adams

April 16, 2010  New York

HealthpointCapital

has acquired

Blue Belt Technologies, Inc.

for $11 million capital investment lending up to $21 million including milestones.

January 19, 2011  New York

HealthpointCapital

has acquired

the Dental Laboratories of:

DTI - Dublin, CA
QDRI - Carmel, IN
Tassi - Chicago, IL
Aesthetic Designs - Hermiston, OR
Cosmo - Ottawa, ON
Lemke - Maplewood, MN

January 1, 2008  New York

HealthpointCapital

has acquired

China Rehabilitation, Ltd.

China Rehabilitation, Ltd. is a company formed in Beijing, China that will provide post-operative, outpatient orthopedic rehabilitation services to private pay patients having recently undergone multiple forms of orthopedic surgical interventions.

April 16, 2010  New York

HealthpointCapital

has committed an initial $3 million to

China Rehabilitation, Ltd.

has led a $10 million growth equity investment

OrthoAccel Technologies, Inc

April 13, 2012  New York

Microdental Laboratories

has acquired

the Dental Laboratories of:

December 2013
Management

John H. Foster - Chairman & Managing Director
Mr. Foster is a 37-year veteran of private equity investing and a successful entrepreneur/executive. He founded Foster Management Company in 1972, which managed seven private equity funds. Mr. Foster was founder and CEO of most of Foster Management’s portfolio companies including Foster Medical Corporation and NovaCare, Inc. He is HEALTHPOINT CAPITAL’s specialist on China: Trustee of Asia Foundation and Asian Cultural Council and a Founder/Advisory Board Member of the Asia Society Policy Institute. He was formerly a Board Member of Avon, Inc. and Corning Incorporated, a Trustee of the Asia Society, the Hospital for Special Surgery in New York, the Burke Rehabilitation Hospital, and Children’s Hospital of Philadelphia, on the Dean’s Council at the Harvard School of Public Health, and an Overseer of the Amos Tuck School of Business Administration.
Amos Tuck School, Dartmouth MBA - Williams College BA

Mortimer Berkowitz III - President & Managing Director
Mr. Berkowitz has 24 years of private equity investing experience and is a seasoned and successful investment professional. Prior to founding HEALTHPOINT CAPITAL in 2002, he had spent more than 20 years in private equity and investment banking. He is Chairman of the Executive Committee of Alphatec Spine, Inc. and Chairman of Blue Belt Technologies, Inc. Mr. Berkowitz is currently a member of the Board of Directors of BioHorizons, Inc. and MicroDental, Inc. He has served as a former Director of Nexa Orthopedics, Inc. and Physician Support Systems, Inc. and is currently a member of the Leadership Council of the Harvard School of Public Health. MD&DI magazine has recognized Mr. Berkowitz as one of the 100 notable people in the medical device industry.
Columbia MBA - Harvard BA
**John C. McCormick - Managing Director**

Mr. McCormick’s is a senior member of the HEALTHPOINTCAPITAL research and investment team and works primarily on private equity investing. He currently serves on the Board of OrthoAccel Technologies, Inc. Mr. McCormick was a Principal at BPI Capital Partners, LLC where he worked closely with Tim Berkowitz. In the 1990s, he was an Associate with Baker Nye, LP, a $600 million private investment fund. He started his career as a macroeconomic and financial analyst at the World Bank in Washington, DC. Mr. McCormick is a member of the Leadership Board of the McGovern Institute of Brain Research at M.I.T. and on the Executive Committee of the Board of Associates of the Whitehead Institute, also at M.I.T.

15 yrs. private equity | MIT MBA - London School of Economics BSc

---

**Laing F. Rikkers - Senior Managing Director**

Ms. Rikkers is an experienced manager with a track record of building corporate infrastructures and effective organizations. Her principle roles at HealthpointCapital are as a member of the Investment Committee and as an advisor to portfolio companies in developing strategy and organization. Ms. Rikkers has been at HealthpointCapital for 10 years and prior she spent 10 years in management positions at Amerada Hess Corporation, the Walt Disney Company and New York-Presbyterian Hospital focused on Organizational Development and Human Resources. Ms. Rikkers is a member of the Board of Directors of HealthpointCapital LLC, BioHorizons, Inc. and MicroDental Laboratories, Inc. and is a Cabinet member of the Salk Excellerators and a member of the Salk Institute Council on the at the Salk Institute for Biological Studies. Columbia MA - Harvard BA

---

**John J. Chopack, Jr. - Managing Director**

Mr. Chopack is an experienced professional in the orthopedic device industry. In addition to his private equity investment experience, his orthopedic industry experience includes time as a Sales Associate in orthopedic products for an independent distributor representing Wright Medical Group and Encore Medical and an internship with Dr. Robert Ruggiero. Prior to joining HEALTHPOINTCAPITAL, Mr. Chopack worked on Wall Street as an associate medical device analyst focused on the orthopedic sector. Mr. Chopack was a primary team member of the Nexa Orthopedics, Inc. investment. He is currently a member of the Board of Directors, Compensation Committee and Audit Committee of BioHorizons, Inc.

11 yrs. private equity | Fordham MBA - Lafayette BA
Ariella P. Golomb, MD - Managing Director

Dr. Golomb brings expertise in medicine and strategy to HealthpointCapital. She is a member of the Firm’s investment team, manages both the firm’s Scientific Advisory Board and other clinical relationships and oversees the operations of the firm. Prior to joining HealthpointCapital, Dr. Golomb was a Project Leader for the Health Care Practice of the Boston Consulting Group, where she advised global life science companies on strategic management issues including product positioning, sales force restructuring and academic medical center alliances. While in business school, Dr. Golomb worked at Wyeth Pharmaceuticals in the Women’s Health Marketing division.

8 yrs. private equity | U Penn MD/MBA - U Penn BA

Petra Hansen - Director of Marketing

Ms. Hansen leads HealthpointCapital’s fundraising and marketing activities. She brings substantial private equity fundraising, marketing and investment experience to the firm. Prior to joining HealthpointCapital, Ms. Hansen worked internationally with private equity managers on fundraising and strategic consulting projects. Previously, Ms. Hansen was an analyst at White Mountains Reinsurance Group working under Jack Byrne, a well-known value investor. She began her career as an investment officer at Dartmouth College, where her responsibilities focused on managing the College’s private equity portfolio. Ms. Hansen is an advisor to social media start-up Newsle.

8 yrs. private equity | Dartmouth MBA - UCLA BA

Joseph A. Fitzpatrick - Chief Financial Officer

Mr. Fitzpatrick spent 18 years working directly with John H. Foster and the Foster Management companies, including Hearing Health Services, The Pet Practice and Access World Wide Communications. Prior to joining Foster Management Company, Mr. Fitzpatrick served as Chief Financial Officer of Interim Systems Corporation, a leading provider of office and medical temporaries, for four years and various financial positions at Kidde, Inc, a Fortune 200 NYSE company for eight years. He started his career at Price Waterhouse & Co. where he earned his CPA certificate.

18 yrs. private equity | Wharton MBA - Saint Francis BA – CPA
## Board of Managers

<table>
<thead>
<tr>
<th>Name</th>
<th>Title and Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortimer Berkowitz III</td>
<td>President &amp; Managing Director, HealthpointCapital</td>
</tr>
<tr>
<td>Jacques Bizot</td>
<td>Founder, Euromed</td>
</tr>
<tr>
<td>Stephen C. Curley</td>
<td>Partner, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo PC</td>
</tr>
<tr>
<td>John H. Foster</td>
<td>Chairman &amp; Managing Director, HealthpointCapital</td>
</tr>
<tr>
<td>Yves-André Istel</td>
<td>Senior Advisor, Rothschild</td>
</tr>
<tr>
<td>R. Ian Molson</td>
<td>Former Deputy Chairman, Molson, Inc.; Former Head of Investment Banking in Europe for Credit Suisse First Boston</td>
</tr>
<tr>
<td>Stephen E. O’Neil</td>
<td>Founder, The O’Neil Group; Former Vice Chairman, City Investing</td>
</tr>
<tr>
<td>Laing F. Rikkers</td>
<td>Senior Managing Director</td>
</tr>
<tr>
<td>John L. Steffens</td>
<td>Managing Partner, Spring Mountain Capital; Former Vice Chairman, Merrill Lynch</td>
</tr>
</tbody>
</table>

## L.P. Advisory Committees

### Fund I

<table>
<thead>
<tr>
<th>Name</th>
<th>Title and Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marcus D. Baker</td>
<td>President, The Baker Companies; Former President &amp; Current Board Member, The Burke Rehabilitation Hospital</td>
</tr>
<tr>
<td>Thomas J. Hillman</td>
<td>Founder &amp; Managing Partner, FTL Capital Partners, LLC</td>
</tr>
<tr>
<td>Kristopher Wood</td>
<td>Advisor to the President, Lurie Investments, Inc.</td>
</tr>
<tr>
<td>Patrick R. Wilmerding</td>
<td>Chairman, Private Signals</td>
</tr>
<tr>
<td>Robert M. Witkoff</td>
<td>Executive Vice President, Chief Investment Officer Int’l, Chubb</td>
</tr>
</tbody>
</table>

### Fund II

<table>
<thead>
<tr>
<th>Name</th>
<th>Title and Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michel de Carvalho</td>
<td>Vice Chairman, Citigroup</td>
</tr>
<tr>
<td>Richard Nye</td>
<td>Chairman of the Investment Committee, Tiedemann Wealth Management</td>
</tr>
<tr>
<td>Kristopher Wood</td>
<td>Advisor to the President, Lurie Investments, Inc.</td>
</tr>
<tr>
<td>Robert M. Witkoff</td>
<td>Executive Vice President, Chief Investment Officer Int’l, Chubb</td>
</tr>
<tr>
<td>Timothy Zee</td>
<td>Co-founder &amp; Managing Director, CSA Capital Limited</td>
</tr>
<tr>
<td>Christopher Wright</td>
<td>Advisory Director, Hansa Capital; Director, Merifin Capital; Chairman, EMAlternatives, LLC</td>
</tr>
</tbody>
</table>

### Fund III

<table>
<thead>
<tr>
<th>Name</th>
<th>Title and Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julia Clark</td>
<td>Director, Private Equity Funds, F &amp; C Investments</td>
</tr>
<tr>
<td>Earl A. Samson</td>
<td>President, Landmark Management, Inc.</td>
</tr>
<tr>
<td>William G. Spears</td>
<td>Chairman, CEO &amp; Co-founder, Spears Abacus</td>
</tr>
</tbody>
</table>
Business Board of Advisors

Yves-André Istel  
Advisory Board Chair;  
Senior Advisor, Rothschild

Colin C. Blaydon  
Director, Center for Private Equity and  
Entrepreneurship; Buchanan Professor  
of Management, Dean Emeritus,  
Tuck School of Business at Dartmouth

Emme Levin Deland  
Senior Vice President for Strategy,  
New York Presbyterian Hospital

Vishakha N. Desai  
President & CEO, Asia Society

Roger S. Fine  
Former corporate Vice President and  
General Counsel of Johnson & Johnson,  
Founding Partner of Windham Venture  
Partners

Richard N. Foster  
Former Director and Senior Partner  
with McKinsey & Company, Senior  
Faculty Fellow at the Yale School of  
Management

Frederick Frank  
Vice Chairman, Peter J. Solomon  
Company

David L. Helfet, M.D.  
Chief of Combined Orthopedic  
Trauma, Hospital for Special Surgery/  
New York Presbyterian Hospital

Richard H. Gelberman, MD  
Chair, Washington University  
Orthopaedics; specialty in hand surgery

Jess H. Lonner, MD  
Director of Knee Replacement Surgery,  
Booth Bartolazzi Balderston Ortho-  
paedics; specialty in knee replacements

Robert L. Buly, MD  
Associate Attending Orthopedic Surgeon,  
Hospital for Special Surgery; specialty  
in joint-preserving surgeries for both hip  
and knee

Andrew Weiland, MD  
Attending Orthopedic Surgeon, Hospital  
for Special Surgery; specialty in hand and  
trauma surgery

Professor Changlong Yu  
Honorable Chairman of the Institute of  
Sports Medicine Third Hospital, Peking  
University Beijing, China

Roger S. Fine  
Former corporate Vice President and  
General Counsel of Johnson & Johnson,  
Founding Partner of Windham Venture  
Partners

Richard N. Foster  
Former Director and Senior Partner  
with McKinsey & Company, Senior  
Faculty Fellow at the Yale School of  
Management

Hansen A. Yuan, MD  
Professor Emeritus, Department of  
Orthopaedic and Neurological Surgery  
at the SUNY Health Science Center

Scott A. Rodeo, MD  
Associate Attending Orthopedic Surgeon,  
Hospital for Special Surgery & The New  
York Presbyterian Hospital; specialty in  
sports medicine injuries of the knee, shoul  
der, ankle and elbow

Lisa Ferrara, PhD  
President of OrthoKinetic Technologies  
LLC, and OrthoKinetic Testing  
Technologies LLC; specialty in biomedical  
engineering of medical devices

William C. Kirby  
T. M. Chang Professor of China Studies at  
Harvard University and Spangler Family  
Professor of Business Administration at the  
Harvard Business School

Richard M. Furlaud  
Chairman, Emeritus Board of Trustees,  
Rockefeller University; Former  
President, Bristol-Myers Squibb  
Company

HealthpointCapital Scientific Advisory Board

David L. Helfet, MD  
Chairman  
Chief of Combined Orthopedic Trauma,  
Hospital for Special Surgery/New York  
Presbyterian Hospital; specialty in  
orthopedic surgery, trauma

Frank P. Cammisa Jr., MD  
Chief, Spinal Surgical Services, Hospital  
for Special Surgery; specialty in spine surgery

Thomas A. Einhorn, MD  
Chairman of the Department of  
Orthopaedic Surgery and Professor of  
Orthopaedic Surgery, Biochemistry,  
and Biomedical Engineering, Boston  
University; specialty in large joint  
replacement

Lisa Ferrara, PhD  
President of OrthoKinetic Technologies  
LLC, and OrthoKinetic Testing  
Technologies LLC; specialty in biomedical  
engineering of medical devices

Richard H. Gelberman, MD  
Chair, Washington University  
Orthopaedics; specialty in hand surgery

Jess H. Lonner, MD  
Director of Knee Replacement Surgery,  
Booth Bartolazzi Balderston Ortho-  
paedics; specialty in knee replacements

Robert L. Buly, MD  
Associate Attending Orthopedic Surgeon,  
Hospital for Special Surgery; specialty  
in joint-preserving surgeries for both hip  
and knee

Andrew Weiland, MD  
Attending Orthopedic Surgeon, Hospital  
for Special Surgery; specialty in hand and  
trauma surgery

Professor Changlong Yu  
Honorable Chairman of the Institute of  
Sports Medicine Third Hospital, Peking  
University Beijing, China

Hansen A. Yuan, MD  
Professor Emeritus, Department of  
Orthopaedic and Neurological Surgery  
at the SUNY Health Science Center

Scott A. Rodeo, MD  
Associate Attending Orthopedic Surgeon,  
Hospital for Special Surgery & The New  
York Presbyterian Hospital; specialty in  
sports medicine injuries of the knee, shoul  
der, ankle and elbow

HealthpointCapital Research  
Scholar at Hospital for Special  
Surgery

Xiaodong Ju MD, PhD  
Attending Doctor & Assistant Researcher,  
Institute of Sports Medicine, Peking  
University Third Hospital

Emeritus

Russell F. Warren, MD  
Surgeon in Chief, Emeritus Hospital for  
Special Surgery; Professor of Orthopedic  
Surgery; specialty in sports medicine
HealthpointCapital Orthobiologic Advisory Committee

Thomas A. Einhorn, MD
Chairman
Chairman of the Department of Orthopaedic Surgery and Professor of Orthopaedic Surgery, Biochemistry, and Biomedical Engineering, Boston University; specialty in large joint replacement

Federico P. Girardi, MD
Hospital for Special Surgery; Associate Attending Orthopaedic Surgeon; specialty in the surgical treatment of spinal disorders including degenerative, deformity, metabolic, fractures, and tumors of the cervical, thoracic and lumbar spine.

John P. Schmitz, DDS, MS, PhD
Health Science Center of San Antonio Adjunct Professor, Division of Research, Department of Orthopaedics, UTHSCSA; Editor of the Academy of Osseointegration Newsletter; specialty Oral and Maxillofacial Surgery

Alexander R. Vaccaro, MD, PhD
The Everett J. and Marion Gordon Professor of Orthopaedic Surgery, Professor of Neurosurgery, Co-Director of the Delaware Valley Spinal Cord Injury Center, Co-Chief Spine Surgery Co-Director Spine Surgery, Thomas Jefferson University and the Rothman Institute, Philadelphia, PA; specialty in spine surgery

Thomas Bauer, MD, PhD
Cleveland Clinic
Deputy Editor for Research for The Journal of Bone and Joint Surgery; specialty in orthopaedic and gastrointestinal pathology; subspecialty in orthopaedic biomaterials research

Frank J. Eismont, MD
Chairman of the Department of Orthopedic Surgery at the University of Miami Miller School of Medicine

J. Patrick Johnson, MD
Director at Cedars Sinai Institute for Spinal Disorders and Co-Director at the Cedars Sinai Hyperhidrosis Center in Los Angeles

Alphatec Spine Scientific Advisory Board

Stephen H. Hochschuler, MD
Chairman
Co-Founder Texas Back Institute, Founding Member of the Board of Directors of the Spine Arthroplasty Society

Bret B. Abshire, MD, MS
Assistant Clinical Professor of Surgery at University of California, San Diego, Vice Chair of Surgery at the Southwest Healthcare System

Gregory Carlson, MD
Partner of Orthopaedic Specialty Institute of Orange County, University of California, Irvine Clinical Assistant Professor of Orthopaedics

Carl Misch, DDS, MDSc
Founder and Director, Misch International Implant Institute; Clinical Professor and Co-Director, Oral Implantology at Temple University

Alexander R. Vaccaro, MD, PhD
The Everett J. and Marion Gordon Professor of Orthopaedic Surgery, Professor of Neurosurgery, Co-Director of the Delaware Valley Spinal Cord Injury Center, Co-Chief Spine Surgery Co-Director Spine Surgery, Thomas Jefferson University and the Rothman Institute, Philadelphia, PA; specialty in spine surgery

Frank Cammisa, MD
Chief of the Spine Service: Hospital for Special Surgery, Associate Professor of Orthopaedic Surgery: Weill Medical College

John P. Schmitz, DDS, MS, PhD
Health Science Center of San Antonio Adjunct Professor, Division of Research, Department of Orthopaedics, UTHSCSA; Editor of the Academy of Osseointegration Newsletter; specialty Oral and Maxillofacial Surgery

James Wilson-MacDonald, MBChB
FRCS, MCH - St. Luke’s Hospital, Oxford. Consultant Spinal and Orthopaedic Surgeon; specialty in spine surgery

BioHorizons Inc. Scientific Advisory Board

Edward P. Allen, DDS, PhD
Center for Advanced Dental Education, Specialist - Oral Plastic Surgery

Steven E. Eckert, DDS
Professor of Dentistry, Mayo Clinic

Michael Pikos, DDS
Founder & Director, Pikos Implant Institute

Edward P. Allen, DDS, PhD
Center for Advanced Dental Education, Specialist - Oral Plastic Surgery

Michael Reddy, DMD, DMSc
Professor and Chair, Department of Periodontics, University of Alabama at Birmingham

Jack Ricci, PhD
Associate Professor, New York University College of Dentistry, Department of Biomaterials and Biomimetics
Blue Belt Technologies Scientific Advisory Board

Prof. Johan Bellemans, MD, PhD  
Professor of Orthopaedic Surgery Catholic University Leuven, Belgium; Chairman Orthopaedic Surgery and Traumatology at Catholic University Hospitals Leuven and Pellenberg, Belgium

Brian Hamlin, MD  
Orthopaedic Surgeon; Associate Director of the Bone and Joint Center of Magee-Womens Hospital of UPMC

Jess H. Lonner, MD  
Rothman Institute; specialty in minimally invasive partial and total knee replacement surgery and robotic-assisted techniques

OrthoAccel Scientific Advisory Board

Michael Liebschner, Ph.D.  
Assistant Professor of BioEngineering, Rice University; Director, Computational and Experimental BioMechanics Laboratory

Dawei Liu, D.D.S., M.S., Ph.D.  
Research Director in the Department of Developmental Sciences/Orthodontics, Marquette University

Jeremy Mao, D.D.S., Ph.D.  
Professor, Columbia University College of Dental Medicine; Director, Tissue Engineering-Regenerative Medicine

Ravindra Nanda, B.D.S., M.D.S., Ph.D.  
Assistant Professor, McGill University; Former President, Canadian Association of Orthodontists

Public Accountants
Ernst & Young

Attorneys
Mintz Levin Cohn Ferris Glovsky & Popeo PC  
Covington & Burling  
Hogan & Hartson